Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · tracked via the Priya Life Science USA tracker

Sponsor

Incyte Corporation

Phase

Observational

Started

2023-08-01

Last updated

2026-08-25

Condition(s) studied

cGVHD

Investigational drug(s) / intervention(s)

Non-Interventional

Non-Interventional: This is an observational study

Study summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years inclusive at the time of signing the ICF * Allogeneic SCT 90 to 180 days prior to enrollment * Able to comprehend and willing to provide informed consent * Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Exclusion Criteria: * There are no exclusion criteria for this study

Primary outcome measure(s)

Overall Burden of cGVHD diagnosis and severity — 36 months

Trial sites (32)

Facility	City	Region	Status
University of Alabama Birmingham	Birmingham	Alabama	Recruiting
Mayo Clinic Arizona	Phoenix	Arizona	Recruiting
City of Hope	Duarte	California	Recruiting
USC Norris Comprehensive Cancer Center	Los Angeles	California	Recruiting
University of Colorado	Aurora	Colorado	Recruiting
Mayo Clinic Jacksonville	Jacksonville	Florida	Recruiting
AdventHealth Orlando	Orlando	Florida	Recruiting
Moffit Cancer Center	Orlando	Florida	Recruiting
Emory University	Atlanta	Georgia	Recruiting
Georgia Cancer Center	Augusta	Georgia	Recruiting
Northwestern University	Chicago	Illinois	Recruiting
Rush University Medical Group	Chicago	Illinois	Recruiting
The University of Chicago	Chicago	Illinois	Recruiting
Loyola University Medical Center	Maywood	Illinois	Recruiting
The University of Kansas Clinical Research Center	Fairway	Kansas	Recruiting
Tulane Cancer Center	New Orleans	Louisiana	Completed
University of Maryland Medical Center	Baltimore	Maryland	Recruiting
Massachusetts Cancer Research Center	Boston	Massachusetts	Recruiting
Corewell Health	Grand Rapids	Michigan	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	Recruiting
The Ohio State University	Columbus	Ohio	Recruiting
Oregon Health Sciences University	Portland	Oregon	Recruiting
Geisinger Health Systems	Danville	Pennsylvania	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	Recruiting
Texas Oncology-Baylor Charles A. Sammons Cancer Center	Dallas	Texas	Recruiting
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	Recruiting
Fred Hutchinson Cancer Research Center	Seattle	Washington	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	Recruiting

More Incyte Corporation trials in the USA

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Active, not recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05919511 on ClinicalTrials.gov ↗ ← All trials in the USA